PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 14, 2026Respirology Case Reports0 citationsOpen Access

SGLT2i Safety and Efficacy in Adults With Cystic Fibrosis

Sodium Glucose‐Like Co‐Transporter 2 Inhibitor ( SGLT2i ) Use in Adults With Cystic Fibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

EJER JohnsonAMAngela MatsonRCRobyn Anderson Cobb

Discussion

Loading...

Member takes

Overview

Case report shows effective SGLT2i use for glycaemic management in adults with Cystic Fibrosis, indicating multi-system benefits.

Key Points

  • To describe the use of SGLT2i in adults with Cystic Fibrosis and their effects.
  • Reported cases of three adults with Cystic Fibrosis receiving SGLT2i.
  • Indications for SGLT2i included glycaemic management and nephropathy.
  • Safety and tolerability were assessed during treatment.
  • All three cases tolerated SGLT2i without side effects.
  • SGLT2i was effective for managing glycaemia in a type 2 diabetes phenotype.
  • Participants had different indications for SGLT2i use related to their nephropathy.

Cite This Study

Johnson et al. (2026) studied this question.

synapsesocial.com/papers/69b4ad8d18185d8a39800eedhttps://doi.org/10.1002/rcr2.70533
View Full Paper
Ask AI
Bookmark
Share